They also looked to see if there were differences based on: 💊Age 💊Weight parameters 💊Probiotic dose There was still no difference🚫 https://t.co/4Q9wzuc3Pi
We have known this for decades they’re still abusing animals for things we already know & getting #Research grants for this same old stuff! Disproving what people know improved their #Health is it #Healthcare #BigPharmas job ?!
RT @PECARNteam: #PECARN #ArticleArchives multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of acu…
RT @PECARNteam: #PECARN #ArticleArchives multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of acu…
RT @PECARNteam: #PECARN #ArticleArchives multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of acu…
Great reminder about a fantastic @PECARNteam study. Unfortunate that probiotics are still being recommended for gastroenteritis at some large institutions despite this compelling data. Classic example of waste in health care.
RT @PECARNteam: #PECARN #ArticleArchives multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of acu…
#PECARN #ArticleArchives multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of acute gastroenteritis (AGE) even when accounting for age, weight, and dose/kg https://t.co/109KC7bX2p @schnadower @HRSAgov @EMSCImprove
RT @jnutritionorg: This double-blind RCT by @schnadower and the @PECARNteam group found no benefit of probiotics versus a placebo for treat…
This double-blind RCT by @schnadower and the @PECARNteam group found no benefit of probiotics versus a placebo for treating acute gastroenteritis in children. Check out the rest of the study published in #JNutr https://t.co/Qmphf1pGWI
https://t.co/lYX3KtR1qq @NEJM
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
3か月から4歳までの小児を対象とした胃腸炎へのプロバイオティクスの効果についてのRCT。北米のPECARN groupによる研究です。メインのアウトカムは中等度以上の胃腸炎、サブは下痢嘔吐の頻度、期間など。嘔吐について以外では統計学的有意差はなかったとのことです。
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
Association between Age, Weight, and Dose and Clinical Response to Probiotics in Children with Acute Gastroenteritis https://t.co/9xDSR36bZP No benefit of using Lactobacillus rhamnosus GG in this study.
Association between Age, Weight, and Dose and Clinical Response to Probiotics in Children with Acute Gastroenteritis: ABSTRACTBackgroundGastroenteritis is a common and impactful disease in childhood. Probiotics are often used to treat acute… https://t.co/N
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
RT @PECARNteam: Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of a…
Hot off the press! #PECARN multicenter double blind RCT showed no benefit ❌for probiotics compared to placebo 💊 for tx of acute gastroenteritis (AGE) even when accounting for age, weight, and dose/kg https://t.co/109KC7bX2p @schnadower @HRSAgov @EMSCImpro
Association between Age, Weight, and Dose and Clinical Response to Probiotics in Children with Acute Gastroenteritis https://t.co/krpRNNP3mw ABSTRACT Background Gastroenteritis is a common and impactful disease in childhood. Probiotics are often used to
RT @PECARNteam: Check out the newest study from @schnadower and team! https://t.co/7hdhuAAHSJ #PECARN https://t.co/oOvAptEPhZ
RT @PECARNteam: Check out the newest study from @schnadower and team! https://t.co/7hdhuAAHSJ #PECARN https://t.co/oOvAptEPhZ
RT @PECARNteam: Check out the newest study from @schnadower and team! https://t.co/7hdhuAAHSJ #PECARN https://t.co/oOvAptEPhZ
RT @PECARNteam: Check out the newest study from @schnadower and team! https://t.co/7hdhuAAHSJ #PECARN https://t.co/oOvAptEPhZ
RT @PECARNteam: Check out the newest study from @schnadower and team! https://t.co/7hdhuAAHSJ #PECARN https://t.co/oOvAptEPhZ
RT @PECARNteam: Check out the newest study from @schnadower and team! https://t.co/7hdhuAAHSJ #PECARN https://t.co/oOvAptEPhZ
Check out the newest study from @schnadower and team! https://t.co/7hdhuAAHSJ #PECARN https://t.co/oOvAptEPhZ
Stephen Freedman @UCalgaryMed , @schnadower, Phil Tarr @WUSTLmed, and co-workers team up within the PECARN Probiotics Study to show no benefit of lactobacillus GG regardless of age, adjusted weight percentile, and dosage! https://t.co/lQAUFJx1VF